Quetiapine-related tardive dyskinesia.
Ghaemi
S N
SN
Ko
J Y
JY
D000085:Acetates / Q000627:therapeutic use; D000328:Adult; D000588:Amines; D000927:Anticonvulsants / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001714:Bipolar Disorder / Q000188:drug therapy*; D003509:Cyclohexanecarboxylic Acids; D003987:Dibenzothiazepines / Q000009:adverse effects* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004409:Dyskinesia, Drug-Induced / Q000453:epidemiology / Q000209:etiology*; D005260:Female; D005632:Fructose / Q000031:analogs & derivatives / Q000627:therapeutic use; D000077206:Gabapentin; D006801:Humans; D008094:Lithium / Q000627:therapeutic use; D000069348:Quetiapine Fumarate; D000077236:Topiramate; D005680:gamma-Aminobutyric Acid
D000085:Acetates; D000588:Amines; D000927:Anticonvulsants; D014150:Antipsychotic Agents; D003509:Cyclohexanecarboxylic Acids; D003987:Dibenzothiazepines; D000077236:Topiramate; D000069348:Quetiapine Fumarate; D005632:Fructose; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin; D008094:Lithium